Imexlab 3000DX

...ratory and a worldwide leader in innovative labora...nsive test menu of highly complex and unique medic... by the University of Utah, ARUP Laboratories' cli...sity teaching hospitals and children's hospitals, ...

Medicine Products:

Meperidine, Urine Melanocyte Stimulation Hormone, Alpha Melanocyte Stimulation Hormone, Gamma MEGX, Urine

(Date:5/16/2008)... ROCHESTER, Minn., May 16 /PRNewswire-USNewswire...format, by Mayo Clinic in conjunction with the,Nat... * A new study being presented at the American Soc...ract #4020), may change treatment practice,in abou...the basis for,proposed changes to the way colorect...

(Date:5/16/2008)... New data from an international, multicenter Phase...l targeted therapy everolimus (RAD001) significant...static kidney cancer whose disease had worsened on...tzer, MD, an attending physician at Memorial Sloan... the findings on May 31 at the annual meeting of t...

(Date:5/16/2008)... PALM BEACH, Fla., May 16 /PRNewswire-USNewswire... more often by Americans, particularly our,childre...individuals, have,significant hearing loss and the...out of every 100 school age children have some for...on to this social and economic problem,is what led...

(Date:5/16/2008)...J Kwon Presents Urban Health Institute with 10,000... of ASFX.org at Playboy Mansion Fundraiser, LOS A...th 2008, hip-hop,and R & B artist J Kwon known bes...Tipsy," will be presenting the Urban Health Instit...acks worth over $50,000. The donation is,being mad...

Breaking Medicine News(10 mins):Health News:New Method Proposed for Determining Which Patients Should Get Treatment for Colorectal Cancer 2 Health News:Drug fends off kidney cancer progression 2 Health News:Huh, What Did You Say?: May is 'Better Hearing and Speech Month' 2 Health News:Huh, What Did You Say?: May is 'Better Hearing and Speech Month' 3 Health News:Everybody in the Club Scream O! 2

[0] New Method Proposed for Determining Which Patients Should Get Treatment for Colorectal Cancer [0] Drug fends off kidney cancer progression [0] Huh, What Did You Say?: May is 'Better Hearing and Speech Month'[0] Everybody in the Club Scream O!

...has brought out some alarming statistics regarding...ems to be on the rise//. Dr. Sheela Basrur, Onta...s continuing. The number of people who are living ...t because of the continuing spread of infection, b...

...rrested a fake doctor and his wife for allegedly c...ospital in a town near here//. Pritam Singh Amarji... Sahib Hospital at Patran town for couples wanting...ses. Their illegal activities came to light when ...

...y in patients with type 2 diabetes demonstrate tha...as chromium picolinate// , in combination with a c...lin sensitivity and glucose control better than th... study, conducted by researchers at Pennington Bio...

...repeat itself and the campaign that took place eig...Princess Alexandra Eye Pavilion// in Lauriston loo...oposed plans to transfer eye operations to St John... force Edinburgh people to make a round trip of ab...

Other Medicine News:Health News:Supplementation with Chromium Picolinate Improves Glycemic Control 2

Report Establishes Increasing Trend in HIV and AIDS among Ontarians Quack Couples Arrested for Conducting Illegal Abortions Supplementation with Chromium Picolinate Improves Glycemic Control Health Board to deal with Another Upcoming Fight

(Date:5/16/2008)...RNewswire-FirstCall/ -- Memory Pharmaceuticals,Cor...several key development,programs at its R&D Day me...eported new clinical data for MEM 1414, its lead P...tivity in humans. In addition, the,Company has nom... from its,5-HT6 antagonist program, and separately...

(Date:5/16/2008)... /- Data from three studies,evaluatin...bin (Hb) levels,and the rate of blood transfusions...n reimbursement for erythropoiesis-stimulating age...ood supply, will be presented at the,American Soci...er this,month. The meeting will take place in Chic...

(Date:5/16/2008)...Results demonstrating that TYKERB and trastuzumab ...sion of progression-free survival (PFS), -- Combi...ide and,outside of the HER2 receptor may create a ...g activity of TYKERB alone despite patients,previ...nd chemotherapy, LONDON and PHILADELPHIA, May 16 ...

(Date:5/16/2008)...iomarkers -- for Lung Cancer Diagnosis and, Identi...f Unknown Primary ...es With High Sensitivity and, Specificity and Co...r Results of microRNA Signature to Identify Tissu...g 90% and Specificity of 99%, REHOVOT, Israel and...

Breaking Medicine Technology:Memory Pharmaceuticals Highlights Progress with Key Programs at its R&D Day 2 Memory Pharmaceuticals Highlights Progress with Key Programs at its R&D Day 3 Memory Pharmaceuticals Highlights Progress with Key Programs at its R&D Day 4 New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 2 New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 3 New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 4 New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 5 New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 6 GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 2 GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 3 GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 4 GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 5 GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 6 GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 7 Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 2 Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 3 Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 4 Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 5 Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 6 Tulane University to receive 2414M for international HIV AIDS program 780 1 Tulane University to receive 2414M for international HIV AIDS program 780 2 Multi Year Compendium of Pharmaceutical Case Studies Available from Best Practices LLC 776 1 Multi Year Compendium of Pharmaceutical Case Studies Available from Best Practices LLC 776 2 Pharmaceutical Manufacturing Quality 3A Optimizing Your Internal Process for FDA Compliance 772 1 Pharmaceutical Manufacturing Quality 3A Optimizing Your Internal Process for FDA Compliance 772 2 Rain Man mice provide model for autism 771 1 Rain Man mice provide model for autism 771 2

[0] Memory Pharmaceuticals Highlights Progress with Key Programs at its R&D Day [0] New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting [0] GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab)[0] Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO)

...(BUSINESS WIRE)--Jun 25, 2007 - Gilead,Sciences, I...a,Phase III clinical trial evaluating the company,...soproxil fumarate or tenofovir,DF) 300 mg as a pot...V) infection, met its primary efficacy endpoint. T...mpany,s once-daily antiviral,drug Hepsera(R) (adef...

...icates 20-50% Improvement in Post-Preservation,Fun...r Cancer,Therapy, BOTHELL, Wash., June 25, 2007 /P... leading developer and marketer of proprietary,hyp...ts for cells,tissues, and organs, today presented...mily of cryopreservation media at the annual,meeti...

Other Medicine Technology:Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 2 Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 3 Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 4 Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 5 Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 6 BioLife Solutions Presents Data on CryoStor at International,Society for Cellular Therapy Annual Meeting 2 BioLife Solutions Presents Data on CryoStor at International,Society for Cellular Therapy Annual Meeting 3 BioLife Solutions Presents Data on CryoStor at International,Society for Cellular Therapy Annual Meeting 4

Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint BioLife Solutions Presents Data on CryoStor at International,Society for Cellular Therapy Annual Meeting

Products	Imexlab 3000DX
Company	Nicolet Vascular
Item	Imexlab 3000DX
Features	Bidirectional Doppler - to detect flow and determine direction. Photoplethysmography (PPG) - to evaluate blood flow in the digits and for assessing venous reflux. Instructional audio tape. One year warranty. Quick reference guide. Two hand-held aneroid cuff inflators. Foot switch. PPG probe, PPG rings, PPG strap, PPG disks.
Description	The Imexlab 3000DX bidirectional vascular testing system offers versatility, portability and optimum convenience for the physician concerned with arterial and venous disease. The system is designed and made by Nicolet Vascular, the premier manufacturer of the vascular diagnostic systems chosen by thousands of vascular laboratories, radiology departments and physicians.
Info	Nicolet Vascular Customer Service: (800) 356-0007